Calise Chris

SEC source: 0001683168-26-001030 · ownership.xml · nonDerivative · entry 2

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,741

F2 · price: Represents a grant of restricted stock issued in connection with an option exchange program where the Reporting Person surrendered underwater options in exchange for a grant of restricted stock.

F3 · ownership.direct: Includes (i) 49,500 shares of common stock that are owned by CJC Investment Trust (a Trust in which Mr. Calise is a control person), and (ii) 47,106 shares of common stock that are issuable under currently exercisable warrants.

SEC source: 0001683168-26-001030 · ownership.xml · nonDerivative · entry 1

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the exercise price of shares purchased upon exercise of stock options.

F3 · ownership.direct: Includes (i) 49,500 shares of common stock that are owned by CJC Investment Trust (a Trust in which Mr. Calise is a control person), and (ii) 47,106 shares of common stock that are issuable under currently exercisable warrants.

SEC source: 0001683168-25-001388 · ownership.xml · derivative · entry 1

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,950

Underlying: Common Stock · 5,700 shares

Expires not disclosed

F1 · security: On March 4, 2025, the reporting person received a grant of 5,700 stock options, as non-qualified options, under the 2022 equity incentive plan.

F2 · derivative.exercise_price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.

F2 · price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Capital Market on the day of grant.

F3 · derivative.exercise_date: Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2025, the next 25% vesting on 6/30/2025, the next 25% vesting on 9/30/25, and the final 25% vesting on 12/31/25.

F4 · derivative.expiration_date: Expiration date is ten years from the day of grant.

SEC source: 0001683168-23-006200 · ownership.xml · nonDerivative · entry 2

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,464,897

F1 · balance_after: Includes (i) 942,117 shares of common stock that are issuable under currently exercisable options and (ii) 7,500 shares of common stock that are issuable upon exercise of options that will become exercisable. Does not include 22,500 shares of common stock that are issuable upon exercise of options that are not currently exercisable and will not become exercisable in the next 60 days.

SEC source: 0001683168-23-006200 · ownership.xml · nonDerivative · entry 1

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,462,315

F1 · balance_after: Includes (i) 942,117 shares of common stock that are issuable under currently exercisable options and (ii) 7,500 shares of common stock that are issuable upon exercise of options that will become exercisable. Does not include 22,500 shares of common stock that are issuable upon exercise of options that are not currently exercisable and will not become exercisable in the next 60 days.

SEC source: 0001683168-23-000424 · ownership.xml · derivative · entry 1

Calise Chris · CIK 0001824769 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F1 · security: On January 27, 2023, the reporting person received a grant of 30,000 stock options, as non-qualified options, under the 2022 equity incentive plan.

F2 · derivative.exercise_price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.

F2 · price: The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.

F3 · derivative.exercise_date: Non-qualified options will vest over 1 year, in four equal installments, with the first 25% vesting on 3/31/2023, the next 25% vesting on 6/30/2023, the next 25% vesting on 9/30/23, and the final 25% vesting on 12/31/23.

F4 · derivative.expiration_date: Expiration date is ten years from the day of grant.

SEC source: 0001213900-22-068387 · ownership.xml · derivative · entry 1

Bull Horn Holdings Sponsor LLC · CIK 0001759065 · 10% owner

Calise Chris · CIK 0001824769 · Director · 10% owner

Striar Robert · CIK 0001824965 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000,000

Underlying: Common Stock · 3,000,000 shares

Expires 2027-10-28

F1 · date: On October 28, 2022, Bull Horn Holdings Corp. ("Bull Horn") completed its initial business combination with Coeptis Therapeutics, Inc., a Delaware corporation ("Coeptis"), and changed its name to Coeptis Therapeutics Holdings, Inc., pursuant to that certain Agreement and Plan of Merger, dated as of April 18, 2022.

F2 · kind: Bull Horn Holdings Sponsor LLC (the "Sponsor") acquired these warrants for a purchase price of $1.00 per warrant in connection with the initial public offering of Bull Horn. The warrants could only become eligible for exercise upon consummation of Bull Horn's initial business combination. Since the exercise of the warrants was contingent upon the closing of the business combination, these warrants were not reported at the time of acquisition. The acquisition is being reported now in connection with the consummation of Bull Horn's initial business combination with Coeptis.

F3 · ownership.direct: The Sponsor is the record holder of the warrants reported herein. Christopher Calise and Robert Striar are the managing members of the Sponsor and have voting and dispositive power over the warrants held by the Sponsor. Each of Mr. Calise and Mr. Striar disclaims any beneficial ownership of the reported warrants other than to the extent of any pecuniary interest he may have therein.

SEC source: 0001213900-20-042561 · ownership.xml · nonDerivative · entry 1

Calise Chris · CIK 0001824769 · Director · Chief Financial Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Bull Horn Holdings Sponsor LLC

Disclosed balance after: 1,875,000

F2 · kind: Mr. Christopher Calise is a managing member of the Sponsor and has voting and investment discretion with respect to the securities held by the Sponsor. As such, he may be deemed to share beneficial ownership of the ordinary shares held directly by the Sponsor.

F3 · shares: As contemplated in connection with the initial public offering of the issuer, 281,250 ordinary shares of the issuer were returned by the Sponsor to the issuer for no consideration and cancelled because the underwriters' over-allotment option was not exercised.

F1 · balance_after: These ordinary shares represent ordinary shares held by Bull Horn Holdings Sponsor LLC (the "Sponsor") acquired pursuant to a subscription agreement by and between the Sponsor and the issuer.

F2 · ownership.nature: Mr. Christopher Calise is a managing member of the Sponsor and has voting and investment discretion with respect to the securities held by the Sponsor. As such, he may be deemed to share beneficial ownership of the ordinary shares held directly by the Sponsor.